Related Experiment Videos
Drug promotion: the Third World revisited
Summary
Pharmaceutical companies show improved drug promotion in developing nations, reducing exaggerated claims and disclosing more adverse reactions. This shift did not negatively impact profits, indicating a positive trend in global pharmaceutical marketing practices.
Area of Science:
- Pharmaceutical Marketing
- Global Health
- Drug Regulation
Background:
- Previous surveys in 1973 and 1980 revealed significant issues with prescription drug promotion in developing countries, including exaggerated claims and downplayed adverse reactions.
- A double standard in pharmaceutical marketing was evident, with less stringent promotion in developing nations compared to developed countries.
Purpose of the Study:
- To assess changes in pharmaceutical drug promotion practices in developing nations and compare them to practices in developed countries.
- To evaluate whether pharmaceutical companies have adopted more ethical and evidence-based marketing strategies globally.
Main Methods:
- An expanded survey of information distributed to physicians in 1984 across the United States, the United Kingdom, and 28 developing nations in Africa, Asia, and Latin America.
- Analysis of promotional materials for 1069 products representing 63 drug entities and fixed combinations from 303 companies.
Main Results:
- Striking improvements were noted, with many pharmaceutical firms demonstrating more restraint in claims, limiting them to scientifically supported evidence.
- Companies showed greater willingness to disclose serious drug hazards, indicating a move away from a double standard in promotion.
- Pharmaceutical companies that abandoned the double standard in drug promotion did not experience significant profit losses.
Conclusions:
- Pharmaceutical drug promotion in developing nations has shown notable improvement regarding claim accuracy and hazard disclosure.
- While progress has been made, there remains a clear need for further enhancements in marketing practices by both multinational and domestic pharmaceutical companies.
- Ethical pharmaceutical marketing, characterized by evidence-based claims and transparent reporting of risks, appears to be a viable and profitable strategy.